Analysts Offer Predictions for OS Therapies FY2030 Earnings

Key Points

• Brookline Capital Markets analyst K. Raja projects FY2030 EPS of $0.42 for OS Therapies versus the current consensus full-year estimate of ($0.52), while the company reported quarterly EPS of ($0.41) on March 31.
• Shares trade around $1.66 with a market cap of about $65.6M, yet analysts carry a "Moderate Buy" consensus and an average target of $18.50 (D. Boral Capital set a $20.00 target), and several institutions have recently increased or initiated positions in the stock.
• OS Therapies is a clinical-stage biopharma developing osteosarcoma treatments, notably the off-the-shelf immunotherapy OST-HER2 and the antibody-drug conjugate platform OST-tADC.

OS Therapies Incorporated (NYSEAMERICAN:OSTX - Free Report) - Investment analysts at Brookline Capital Markets issued their FY2030 EPS estimates for shares of OS Therapies in a note issued to investors on Friday, May 1st. Brookline Capital Markets analyst K. Raja anticipates that the company will earn $0.42 per share for the year. The consensus estimate for OS Therapies' current full-year earnings is ($0.52) per share.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.41) earnings per share for the quarter.

Separately, D. Boral Capital restated a "buy" rating and set a $20.00 price target on shares of OS Therapies in a report on Thursday, April 30th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, OS Therapies presently has an average rating of "Moderate Buy" and an average target price of $18.50.

OS Therapies Stock Up 3.1%

NYSEAMERICAN:OSTX opened at $1.66 on Tuesday. The firm has a market capitalization of $65.62 million, a PE ratio of -1.68 and a beta of -1.34. The stock's 50-day simple moving average is $1.45 and its 200 day simple moving average is $1.56. OS Therapies has a twelve month low of $1.15 and a twelve month high of $2.57.

Institutional Trading of OS Therapies

Several institutional investors have recently made changes to their positions in the company. CM Management LLC boosted its holdings in shares of OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company's stock worth $784,000 after buying an additional 25,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of OS Therapies by 31.1% during the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company's stock valued at $344,000 after purchasing an additional 58,350 shares in the last quarter. Millennium Management LLC bought a new position in shares of OS Therapies in the third quarter worth $183,000. Two Sigma Investments LP purchased a new stake in shares of OS Therapies in the third quarter worth $169,000. Finally, Virtu Financial LLC boosted its stake in OS Therapies by 252.0% during the third quarter. Virtu Financial LLC now owns 75,801 shares of the company's stock valued at $149,000 after buying an additional 54,269 shares during the period.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.